Pyrrolo[2,3-d]Pyrimidine Crystallization for Pharmaceutical Forms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing manufacturing processes for N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide lack the ability to produce crystalline forms with improved properties suitable for pharmaceutical dosage forms, particularly for oral and topical applications.
Innovation Solution
A novel process is developed to prepare crystalline and non-crystalline forms of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, utilizing specific reaction conditions and reagents to achieve desired structural and diffraction patterns, enabling the production of pharmaceutical-grade compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing manufacturing processes are used, then the compound can be produced, but the crystalline form with improved properties suitable for pharmaceutical dosage forms cannot be obtained
Solution Approach 1:
The patent applies parameter changes by modifying reaction conditions including temperature ranges (0°C to reflux), solvent systems (ethyl acetate, isopropanol, water), and pH control during the synthesis process to obtain specific crystalline forms with improved properties suitable for pharmaceutical dosage forms
Solution Approach 2:
The patent utilizes phase transitions by controlling the crystallization process from solution to obtain distinct crystalline forms (Form I, Form II, etc.) with different properties, enabling selection of optimal forms for pharmaceutical applications based on solubility, stability, and bioavailability requirements
2Reliability
If crystalline forms with improved properties are produced, then therapeutic efficacy is enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-determining optimal reaction parameters and crystallization conditions through systematic experimentation, establishing standardized protocols that reliably produce desired crystalline forms with enhanced therapeutic efficacy while managing process complexity through predefined procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process yields crystalline forms with enhanced properties, suitable for pharmaceutical formulations, providing improved therapeutic efficacy in treating conditions such as lupus, rheumatoid arthritis, and other autoimmune disorders.
Implementation Method 1
The present invention is directed to a process for preparing a crystalline or noncrystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide free base
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.